• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CISPLATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • CISPLATIN chembl:CHEMBL11359 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    PLATINOL
    CIS-DDP
    INT-230-6 COMPONENT CISPLATIN
    PLATINOL-AQ
    CISPLATIN
    CISPLATINUM
    INT230-6 COMPONENT CISPLATIN
    NSC-119875
    CIS-PLATINUM II
    CIS-DIAMMINEDICHLOROPLATINUM(II)
    CDDP
    rxcui:2555
    chembl:CHEMBL11359
    chemidplus:15663-27-1
    drugbank:00515
    pubchem.compound:5702198

    Drug Info:

    (8 More Sources)

    Publications:

    Xu et al., 2014, Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis., J Transl Med
    Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer
    Clemens E et al., 2020, Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study., Pharmacogenomics J
    Sawers et al., 2014, Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines., Br. J. Cancer
    Goričar K et al., 2015, Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma., Cancer Epidemiol
    Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
    Booton R et al., 2006, Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer., J Thorac Oncol
    Kimura S et al., 2004, The relationship of the human glutathione S-transferase P1 polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma., Int J Mol Med
    Hour et al., Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines., Anticancer Res.
    Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
    Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
    O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
    Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
    Sheffield et al., 2015, Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing., PLoS ONE
    Castagna et al., 2004, A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431., Proteomics
    Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.
    Sen et al., 2017, CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib., Cancer Res.
    Gadhikar et al., 2013, Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53., Mol. Cancer Ther.
    Carrillo et al., 2015, Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells., Mol. Cancer Res.
    Chang et al., 2015, The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity., Mol. Cancer Ther.
    Richer et al., 2017, WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer., Cancer Res.
    Zhang et al., 2015, Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53., Cancer Res.
    Han et al., 2008, Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer., Cancer
    Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
    Michels et al., 2013, Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer., Cell Cycle
    Fransson et al., 2016, Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer., J Ovarian Res
    Mohell et al., 2015, APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells., Cell Death Dis
    Zamble et al., 1998, p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells., Proc. Natl. Acad. Sci. U.S.A.
    Nakata et al., 1996, [Association between p53 expression and chemosensitivity in advanced and recurrent gastric cancer]., Gan To Kagaku Ryoho
    Kigawa et al., 2002, Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells., Gynecol. Oncol.
    Reles et al., 2001, Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer., Clin. Cancer Res.
    Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol
    Zhang et al., 2013, Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer., Carcinogenesis
    Kang et al., 2016, ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models., Lung Cancer
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Xu JL et al., 2012, Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population., Asian Pac J Cancer Prev
    Sasano et al., 2015, Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary., Mol. Cancer Res.
    Barni et al., 1987, Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients., Tumori
    Xu X et al., 2012, Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients., Clin Exp Pharmacol Physiol
    Xu X et al., 2012, Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients., Lung Cancer
    Wang et al., 2003, [Study on the expression of DNA excision repair biomarkers in cispatin-treated lung cancer cell line]., Zhonghua Yu Fang Yi Xue Za Zhi
    Caronia et al., 2009, Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients., Pharmacogenomics J.
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
    Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
    Lamas MJ et al., 2011, Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer., Pharmacogenomics
    Drögemöller BI et al., 2017, Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer., JAMA Oncol
    Spracklen TF et al., 2017, Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin., Pharmacogenomics J
    Lanvers-Kaminsky C et al., 2015, Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity., Pharmacogenomics
    Ciarimboli G et al., 2012, Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients., Clin Cancer Res
    Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
    Gately et al., 1996, Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153., Br. J. Cancer
    Johnsson et al., 1999, Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts., Cancer Chemother. Pharmacol.
    Maki et al., 2005, Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines., Oral Oncol.
    Chen et al., 1994, O6-methylguanine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy., Gynecol. Oncol.
    Rosell et al., 2003, Targeted therapy in combination with gemcitabine in non-small cell lung cancer., Semin. Oncol.
    Nie et al., 2013, The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer., Cancer Biomark
    Ryu JS et al., 2011, Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum., J Thorac Oncol
    Rosell R et al., 2004, Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
    Choeyprasert W et al., 2013, Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms., J Pediatr Hematol Oncol
    Riedemann L et al., 2008, Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin., Pharmacogenomics J
    Han JY et al., 2010, Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy., Pharmacogenomics J
    Mueller et al., 2003, Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer., Cancer Res.
    Baltaci et al., 2001, P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours., BJU Int.
    Chung et al., 2014, A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma., Ann. Oncol.
    Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
    Cui LH et al., 2011, Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC., Pharmacogenomics
    Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
    Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
    Patiño-García A et al., 2009, Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression., J Pediatr
    Arjumand et al., 2016, Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells., Oncotarget
    Kool et al., 1997, Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines., Cancer Res.
    Han JY et al., 2014, A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy., Pharmacogenomics J
    Sulkowski et al., 2017, 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity., Sci Transl Med
    Raaphorst et al., 2005, Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair., Oncol. Rep.
    Nylén et al., 1998, Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil., Acta Oncol
    Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
    Newman et al., 1988, Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin., Biochem. Pharmacol.
    Cui et al., 2012, Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity., Clin. Cancer Res.
    Chen et al., 2000, [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins]., Zhonghua Fu Chan Ke Za Zhi
    Alakus et al., 2009, GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer., Pharmacogenomics J.
    Jaboin et al., 2002, Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway., Cancer Res.
    Brozovic et al., 2001, Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia., Neoplasma
    Li et al., 1998, Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells., Int. J. Oncol.
    Li et al., Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line., Anticancer Res.
    Goldberg et al., 2001, An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin., Int. J. Radiat. Oncol. Biol. Phys.
    Li et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells., Anticancer Res.
    Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
    Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
    Rumiato E et al., 2013, ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy., Pharmacogenet Genomics
    Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
    Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
    Kim HS et al., 2009, Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study., Gynecol Oncol
    Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
    Kawashima et al., 2011, Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer., Clin. Cancer Res.
    Usanova et al., 2010, Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression., Mol. Cancer
    Postel-Vinay et al., 2013, A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer., Oncogene
    Cheng et al., 2013, PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells., Carcinogenesis
    Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
    Ceppi P et al., 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine., Ann Oncol
    Rosell et al., 2006, Pharmacogenomics and gemcitabine., Ann. Oncol.
    Kerley-Hamilton et al., 2005, A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma., Oncogene
    Clark et al., 1994, Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines., Cancer Immunol. Immunother.
    Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
    Miyashita et al., 2003, Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin., Oral Oncol.
    Nakayama et al., Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines., Oncol. Rep.
    Xing et al., 2006, A mouse model for the molecular characterization of brca1-associated ovarian carcinoma., Cancer Res.
    Wang et al., 2016, RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., J. Clin. Invest.
    Golan T et al., 2014, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers., Br J Cancer
    de Jong C et al., 2017, Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman., Br J Clin Pharmacol
    Thiesen S et al., 2017, TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity., Pharmacogenet Genomics
    Hagleitner MM et al., 2014, Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts., PLoS One
    Carleton BC et al., 2014, Genetic markers of cisplatin-induced hearing loss in children., Clin Pharmacol Ther
    Lanvers-Kaminsky C et al., 2014, Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity., Clin Pharmacol Ther
    Yang JJ et al., 2013, The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer., Clin Pharmacol Ther
    Pussegoda K et al., 2013, Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children., Clin Pharmacol Ther
    Ross CJ et al., 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy., Nat Genet
    Khrunin AV et al., 2014, Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer., Pharmacogenomics
    Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
    Olas et al., 1998, Modulation of cisplatin toxicity in blood platelets by glutathione depletion., Anticancer Drugs
    Go et al., 1997, Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro., Clin. Exp. Metastasis
    Vendetti et al., 2015, The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo., Oncotarget
    Nakayama et al., 2005, Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets., J. Pharmacol. Sci.
    Iida et al., 1999, Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells., Int. J. Cancer
    van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
    Siegsmund et al., 1999, Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins., Urol. Res.
    Watanabe et al., 2003, Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs., Auris Nasus Larynx
    O'Donnell PH et al., 2016, Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer., Clin Genitourin Cancer
    O'Flaherty et al., 2002, Cytotoxicity of paclitaxel or cisplatin on carcinoma cell lines is not inhibited by leukemia inhibitory factor (LIF)., Growth Factors
    Boyle et al., 2001, The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin., Cancer Chemother. Pharmacol.
    Smith et al., 1997, The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity., Exp. Cell Res.
    Smith et al., 2000, p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes., Mol. Cell. Biol.
    Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
    Yazlovitskaya et al., Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin., Anticancer Res.
    Cao et al., 2008, Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling., Carcinogenesis
    Nam et al., 2016, Src as a Therapeutic Target in Biliary Tract Cancer., Mol. Cancer Ther.
    Nomura et al., Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells., Urol. Oncol.
    Li et al., 2001, Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins., Endocrinology
    Cho et al., 2008, Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance., Cancer Lett.
    Patrick et al., 1997, High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin-damaged DNA., Biochim. Biophys. Acta
    Kawahara et al., 1996, Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin., Cancer Res.
    Vos HI et al., 2016, Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma., Pharmacogenet Genomics
    Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
    Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics
    Kiyozuka et al., Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells., Anticancer Res.
    Romerius P et al., 2011, Estrogen receptor α single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors., Pharmacogenet Genomics
    Moers et al., 1999, Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin., Int. J. Cancer
    Yilmaz et al., 2004, The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats., Pharmacol. Res.
    Okegawa et al., 2004, Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer., J. Urol.
    Yang Z et al., 2018, Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy., EBioMedicine
    Xie X et al., 2019, FGFR<sup>3S249C</sup> mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells., Exp Ther Med
    Sakano S et al., 2010, Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer., Pharmacogenomics
    Beretta et al., Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells., Ultrastruct Pathol
    Russo et al., 2006, E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents., Cancer Res.
    Bell et al., 2016, SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Zhang et al., 2006, Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line., BMC Cancer
    Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
    Ghazizadeh, 2003, Cisplatin may induce frataxin expression., J Nippon Med Sch
    Li et al., 2000, [Effects of the expression of mouse metallothionein-I gene in human HeLa cell line on drug resistance]., Wei Sheng Yan Jiu
    Harding et al., 2013, Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer., Sci Transl Med
    Yamaguchi et al., 2007, Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer., Respirology
    van Hensbergen et al., 2004, Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts., Clin. Cancer Res.
    Ding et al., 2013, Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells., Tumour Biol.
    Scartozzi M et al., 2013, Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients., Pharmacogenomics
    Mutze et al., 2011, DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer., Eur. J. Cancer
    Shirasaka, 1990, [Clinical study of nephrotoxicity following cis-diamminedichloroplatinum (II) (CDDP) combination chemotherapy assessed by 131I-OIH renogram]., Nihon Igaku Hoshasen Gakkai Zasshi
    Kotoh et al., 1994, Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells., Cancer Res.
    Schmeiser et al., 1999, The fate of E- and P-cadherin during the early stages of apoptosis., Cell Death Differ.
    Spracklen TF et al., 2014, Genetic variation in Otos is associated with cisplatin-induced ototoxicity., Pharmacogenomics
    Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.
    Lee et al., 2005, Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line., Gynecol. Oncol.
    Mimnaugh et al., 2000, Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors., Biochem. Pharmacol.
    Xu X et al., 2013, The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients., Lung Cancer
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Wu H et al., 2013, Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis., Pharmacogenomics
    Narumiya K et al., 2011, Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer., Pharmacogenomics
    McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
    Ono et al., 2001, Loss of p73 induction in a cisplatin-resistant bladder cancer cell line., Mol Urol
    Kolesar JM et al., 2002, Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue., Int J Oncol
    Beltran et al., 2015, Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response., JAMA Oncol
    Suchi K et al., 2011, Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells., Anticancer Res
    Gao W et al., 2012, MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer., Cancer Biol Ther
    Xie et al., 2017, CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner., Oncol. Rep.
    Roberts D et al., 2005, Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells., Br J Cancer
  • CISPLATIN   LRP2

    Interaction Score: 1.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31666714 23274376 17457342


    Sources:
    PharmGKB

  • CISPLATIN   OTOS

    Interaction Score: 1.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31666714 25410892


    Sources:
    PharmGKB

  • CISPLATIN   XPC

    Interaction Score: 1.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21047201 19434073


    Sources:
    PharmGKB

  • CISPLATIN   ACYP2

    Interaction Score: 1.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31666714 26928270


    Sources:
    PharmGKB

  • CISPLATIN   MIR21

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22237007


    Sources:
    CIViC

  • CISPLATIN   FANCA

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26181256


    Sources:
    CIViC

  • CISPLATIN   CSNK2A3

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27150640


    Sources:
    PharmGKB

  • CISPLATIN   KRT20

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15017198


    Sources:
    NCI

  • CISPLATIN   RARS1

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27150640


    Sources:
    PharmGKB

  • CISPLATIN   DRAM1

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15940259


    Sources:
    NCI

  • CISPLATIN   SLC16A5

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31666714


    Sources:
    PharmGKB

  • CISPLATIN   ERCC1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9772291 9703867 11163512 10810335 29662106 27498158 25069034 23962907 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 19203783 18347182 21177407 20846399 23934192 23275151 17229776 16980606 16807441


    Sources:
    NCI CIViC PharmGKB

  • CISPLATIN   KLC3

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 22188361 22026922 21449681 19434073


    Sources:
    PharmGKB

  • CISPLATIN   SLC31A1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22725681 22516052


    Sources:
    PharmGKB

  • CISPLATIN   MTR

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 21605004 19159907


    Sources:
    PharmGKB

  • CISPLATIN   EIF3A

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23127338


    Sources:
    PharmGKB

  • CISPLATIN   MLLT3

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27150640


    Sources:
    PharmGKB

  • CISPLATIN   BIRC7

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23188704


    Sources:
    CIViC

  • CISPLATIN   MT1F

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12520915


    Sources:
    NCI

  • CISPLATIN   FXN

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12928720


    Sources:
    NCI

  • CISPLATIN   LIG3

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24533712


    Sources:
    PharmGKB

  • CISPLATIN   MUTYH

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24533712


    Sources:
    PharmGKB

  • CISPLATIN   MDH2

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15225672


    Sources:
    NCI

  • CISPLATIN   TERC

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10769656


    Sources:
    NCI

  • CISPLATIN   GALNT18

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27150640


    Sources:
    PharmGKB

  • CISPLATIN   DFFB

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12927282


    Sources:
    NCI

  • CISPLATIN   MT1H

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10422815


    Sources:
    NCI

  • CISPLATIN   REV1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   DCBLD1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23478653


    Sources:
    PharmGKB

  • CISPLATIN   UBE2I

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19859084


    Sources:
    PharmGKB

  • CISPLATIN   SLC22A2

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28448657 27457817 25823781 22223530 21902499


    Sources:
    PharmGKB

  • CISPLATIN   ERCC2

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12839662 19434073 29662106 22188361 22026922 21449681


    Sources:
    NCI CIViC PharmGKB OncoKB

  • CISPLATIN   ATP7B

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15213293 12509969 11605050


    Sources:
    NCI

  • CISPLATIN   GALNT14

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31611591 21635146


    Sources:
    PharmGKB

  • CISPLATIN   CDH17

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10381631


    Sources:
    NCI

  • CISPLATIN   CMPK1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21642870


    Sources:
    PharmGKB

  • CISPLATIN   GABPA

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18036733


    Sources:
    NCI

  • CISPLATIN   GPX5

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CISPLATIN   GCLM

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10399958


    Sources:
    NCI

  • CISPLATIN   GADD45A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9013707 10779360


    Sources:
    NCI

  • CISPLATIN   H2AW

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11008128


    Sources:
    NCI

  • CISPLATIN   PPP1R13L

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   POLR1G

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   GCLC

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9660546


    Sources:
    NCI

  • CISPLATIN   CDC25C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9743457


    Sources:
    NCI

  • CISPLATIN   RRM1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12917817 24595080 21642870 14977831


    Sources:
    NCI CIViC PharmGKB

  • CISPLATIN   TP73

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11689148


    Sources:
    NCI

  • CISPLATIN   AQP9

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12396244


    Sources:
    NCI

  • CISPLATIN   ADH1C

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24533712


    Sources:
    PharmGKB

  • CISPLATIN   FANCC

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16243825


    Sources:
    CIViC

  • CISPLATIN   XRCC5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15944802


    Sources:
    NCI

  • CISPLATIN   NF2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25798586


    Sources:
    CIViC

  • CISPLATIN   STAT1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15726096


    Sources:
    CIViC

  • CISPLATIN   ACSS2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CISPLATIN   REV3L

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   COMT

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28560854 28448657 28445188 25551397 25141953 24642735 23820299 23588304 19898482


    Sources:
    PharmGKB

  • CISPLATIN   GRP

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17207039


    Sources:
    NCI

  • CISPLATIN   SMARCA4

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26671993


    Sources:
    CIViC

  • CISPLATIN   EPHX1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24533712


    Sources:
    PharmGKB

  • CISPLATIN   MTHFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 27995989 21605004 20634689 19307503 19159907


    Sources:
    PharmGKB

  • CISPLATIN   HMGB1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9427537 8968078


    Sources:
    NCI

  • CISPLATIN   LIF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12519017 11800022


    Sources:
    NCI

  • CISPLATIN   ATR

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12894503


    Sources:
    NCI

  • CISPLATIN   MAP3K1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CISPLATIN   BRCA2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Veliparib + Vinorelbine
    Indication/Tumor Type Her2-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    25193512 26801247 29338080 25847936


    Sources:
    JAX-CKB CIViC

  • CISPLATIN   GSTP1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25010864 31666714 25592234 22188361 19786980 17409936 15254763 11062746


    Sources:
    NCI CIViC PharmGKB

  • CISPLATIN   HEXB

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2089371


    Sources:
    NCI

  • CISPLATIN   GSTA1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22188361


    Sources:
    PharmGKB

  • CISPLATIN   MYCN

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12439032


    Sources:
    NCI

  • CISPLATIN   GSTT1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12851839


    Sources:
    NCI

  • CISPLATIN   ABCC3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31666714 27457817 25141953 22016816


    Sources:
    PharmGKB

  • CISPLATIN   XRCC1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    CIViC

  • CISPLATIN   ANPEP

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14871998


    Sources:
    NCI

  • CISPLATIN   SLC19A1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    PharmGKB

  • CISPLATIN   SMAD4

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22753594


    Sources:
    JAX-CKB

  • CISPLATIN   MGMT

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16043385 8314134


    Sources:
    NCI

  • CISPLATIN   XIAP

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15610860 11145600


    Sources:
    NCI

  • CISPLATIN   HSPA8

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15378690


    Sources:
    NCI

  • CISPLATIN   ABCC4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9270026 23478653


    Sources:
    NCI PharmGKB

  • CISPLATIN   E2F1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16849574


    Sources:
    NCI

  • CISPLATIN   IFNG

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8044830


    Sources:
    NCI

  • CISPLATIN   DDIT3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8554977 10071988


    Sources:
    NCI

  • CISPLATIN   BRCA1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    16982732 27454289 26801247 25193512 29338080 25072261 25847936


    Sources:
    ClearityFoundationBiomarkers JAX-CKB NCI CIViC

  • CISPLATIN   NAT2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24533712


    Sources:
    PharmGKB

  • CISPLATIN   TPMT

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • CISPLATIN   FAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9935158


    Sources:
    NCI

  • CISPLATIN   RAF1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CISPLATIN   CXCR4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27922681


    Sources:
    CIViC

  • CISPLATIN   NQO1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12370763


    Sources:
    PharmGKB

  • CISPLATIN   TGM2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18667446


    Sources:
    NCI

  • CISPLATIN   BCL2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12543810 11350408


    Sources:
    ClearityFoundationBiomarkers NCI

  • CISPLATIN   CYP2E1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22188361


    Sources:
    PharmGKB

  • CISPLATIN   STK11

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture

    PMIDs:
    28652249


    Sources:
    JAX-CKB

  • CISPLATIN   NRG1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23390248


    Sources:
    CIViC

  • CISPLATIN   IL6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21273582


    Sources:
    CIViC

  • CISPLATIN   PLAU

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9219734


    Sources:
    NCI

  • CISPLATIN   DNMT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21458988


    Sources:
    CIViC

  • CISPLATIN   HTR4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16079468


    Sources:
    NCI

  • CISPLATIN   HSPA4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11478701


    Sources:
    NCI

  • CISPLATIN   AURKA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25082261 25924824


    Sources:
    CIViC

  • CISPLATIN   PRL

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2953096


    Sources:
    NCI

  • CISPLATIN   CHEK1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28490518


    Sources:
    CIViC

  • CISPLATIN   GNAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19274060


    Sources:
    CIViC

  • CISPLATIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Perifosine
    Indication/Tumor Type ovarian clear cell carcinoma
    Response Type predicted – sensitive

    PMIDs:
    22901187 25519148


    Sources:
    JAX-CKB PharmGKB

  • CISPLATIN   TYMS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3337743


    Sources:
    NCI

  • CISPLATIN   VEGFA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24090479


    Sources:
    PharmGKB

  • CISPLATIN   MYC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28490518


    Sources:
    CIViC

  • CISPLATIN   FGFR3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29941343 31316618


    Sources:
    CIViC

  • CISPLATIN   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy APR-246 + Cisplatin
    Indication/Tumor Type lung small cell carcinoma
    Response Type sensitive

    PMIDs:
    23839309 25964101 25376608 28652249 26294215 18618574 25567130 23428903 27179933 26086967 9600935 8678559 11812076 11595686 14514923


    Sources:
    JAX-CKB NCI CIViC

  • CISPLATIN   NTRK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12438277


    Sources:
    NCI

  • CISPLATIN   NRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CISPLATIN   BAX

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15790433


    Sources:
    NCI

  • CISPLATIN   ABCC1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11372415


    Sources:
    NCI

  • CISPLATIN   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MK-1775 + Cisplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive

    PMIDs:
    25081901 27040853 28652249


    Sources:
    JAX-CKB CIViC

  • CISPLATIN   ATM

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6738 + Cisplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    26517239


    Sources:
    JAX-CKB

  • CISPLATIN   ALK

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dalantercept + Cisplatin
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    26373572


    Sources:
    JAX-CKB

  • CISPLATIN   SRC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bosutinib + Cisplatin
    Indication/Tumor Type biliary tract cancer
    Response Type sensitive

    PMIDs:
    27196758


    Sources:
    JAX-CKB

  • CISPLATIN   PIK3CA

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – resistant

    PMIDs:
    27489350


    Sources:
    JAX-CKB CIViC PharmGKB

  • CISPLATIN   G6PD

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15225672


    Sources:
    NCI

  • CISPLATIN   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 23746184 22016816 21332314 20530282


    Sources:
    PharmGKB

  • CISPLATIN   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ER2 + Cisplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23764753 27040853


    Sources:
    JAX-CKB CIViC

  • CISPLATIN   FGFR1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Etoposide + GSK3052230
    Indication/Tumor Type lung small cell carcinoma
    Response Type sensitive

    PMIDs:
    23536011


    Sources:
    JAX-CKB

  • CISPLATIN   RAD52

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24533712


    Sources:
    PharmGKB

  • CISPLATIN   TOP1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8205547


    Sources:
    NCI

  • CISPLATIN   ABCC2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   RECQL

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16978399


    Sources:
    NCI

  • CISPLATIN   RGS4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   ESR1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21430602


    Sources:
    PharmGKB

  • CISPLATIN   PTEN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   NR1I2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CISPLATIN   MPHOSPH8

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   KAT2A

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CISPLATIN   ALOX15

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   APEX1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   CBX1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Talazoparib
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive

    PMIDs:
    28148839


    Sources:
    JAX-CKB

  • CISPLATIN   HPGD

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   KDM4E

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   ALDH1A1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   HSD17B10

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   MAPT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CISPLATIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NCI: CISPLATIN

    • Version: 14-September-2017

    Alternate Names:
    C376 NCI drug code

    Drug Info:

    Publications:
    Castagna et al., 2004, A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431., Proteomics
    Kool et al., 1997, Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines., Cancer Res.
    Raaphorst et al., 2005, Cisplatin sensitization by concurrent mild hyperthermia in parental and mutant cell lines deficient in homologous recombination and non-homologous endjoining repair., Oncol. Rep.

  • NCI: CISPLATINUM

    • Version: 14-September-2017

    Alternate Names:
    C376 NCI drug code

    Drug Info:

    Publications:
    Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.

  • NCI: CDDP

    • Version: 14-September-2017

    Alternate Names:
    C376 NCI drug code

    Drug Info:

    Publications:
    Kiyozuka et al., Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells., Anticancer Res.
    Chen et al., 2000, [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins]., Zhonghua Fu Chan Ke Za Zhi
    Ono et al., 2001, Loss of p73 induction in a cisplatin-resistant bladder cancer cell line., Mol Urol

  • JAX-CKB: Cisplatin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.
    Chang et al., 2015, The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity., Mol. Cancer Ther.
    Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.

  • PharmGKB: cisplatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Clemens E et al., 2020, Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study., Pharmacogenomics J
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics

  • CIViC: CISPLATIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Arjumand et al., 2016, Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells., Oncotarget
    Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer
    Xu et al., 2014, Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis., J Transl Med

  • DTC: CISPLATIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL11359 ChEMBL Drug ID
    CHEMBL2068237 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Cisplatin

    • Version: 2020.06.01

    Alternate Names:
    D0U5HU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL11359

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: CISPLATIN

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Cisplatin

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Cisplatin

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21